What imaging and tissue can tell us after local treatment
Imaging maps lesions and treatment exposure; tissue samples biology at a particular place and time. Neither alone proves a systemic immune benefit.
Before you start: Local injury and immune signals separates physical destruction from priming. TCR sequencing explains receptor identity and specificity.
Start with the measured quantity
| Measurement | What it can establish | What it does not establish alone |
|---|---|---|
| CT or MRI | Anatomy, lesion dimensions and change under a defined assessment | Viable-cell count or cause of a response |
| Planning imaging | Geometry, motion and dose constraints | Later tumor control |
| Target PET | Tracer distribution and uptake at the scan time | Universal target density or safe exposure for another therapy format |
| Pathology or immunohistochemistry | Sampled morphology and protein localization | Whole-body uniformity or live-cell killing |
| RNA profiling | Sampled expression under the preparation used | Surface protein accessibility or dependence |
| TCR (T-cell receptor) sequencing | Sampled clones and their abundance | Antigen specificity, killing or clinical benefit |
The specimen, timepoint and denominator belong beside the result. For example, CD8 cells as a fraction of all cells differs from CD8 cells per tissue area. A percentage can rise because tumor cells declined even if the number of CD8 cells did not increase.
Tissue is consumed even when it is archived
Pathology takes priority in a clinical specimen. Sections, curls and cores consumed for immunohistochemistry, sequencing or other assays are no longer available for another use. Existing tissue can avoid a new procedure, but it is not “zero tissue cost.”
Fixed tissue can support many histology and molecular assays. Fresh-frozen tissue preserves some molecular measurements but usually does not provide viable cells. Controlled viable-cell cryopreservation is different from flash freezing. Single-cell immune experiments and functional models need method-compatible inputs.
Before combining assays, ask the laboratory for its actual input, tumor-content criteria, expected failure rate and return of unused material. There is no generic three-core budget that guarantees enough material for all tests.
Target validation is a chain
RNA may motivate a target hypothesis. Protein staining adds localization. Surface accessibility, normal-tissue expression and tracer uptake add other evidence. These steps can disagree. A tumor-specific RNA signal can coexist with substantial normal-organ uptake of a binder.
For radioligands, diagnostic imaging and therapeutic dosimetry answer related but distinct questions. Some validated pathways use PET selection; other products use different imaging or measurements. A single scan is not universally sufficient to calculate therapeutic exposure. The exact product and protocol determine requirements.
Sampling before and after treatment
A post-treatment biopsy can measure local cell composition, expression or damage markers. Its timing and location strongly affect interpretation. A lesion center, viable rim and distant site can look different. Repeated biopsy adds bleeding, infection and organ-specific risk; it is a clinical or protocol decision, not an automatic research step.
A useful comparison prespecifies sites, timing, assays, denominator and controls. An increase in T cells can support recruitment but does not by itself prove tumor-specific priming. Pairing receptors with stimulation or killing experiments can address specificity; patient outcomes remain a later evidence layer.
A worked example
A treated lesion changes from 20% to 60% immune cells. One explanation is recruitment. Another is loss of cancer cells changing the denominator. A third is sampling a different region. Absolute density, matched location and assay details help distinguish them. Even real recruitment does not isolate which component of a combination caused it.
Try it
Can archived RNA expression prove a recurrent lesion has enough surface target for a new radioligand?
Answer: No. The sample is from another time and RNA is a different quantity. Current, product-specific validation is needed where the decision depends on it.
Explain it back: “Every assay answers one question in one sample, and combining them needs compatible timing and units.”
Explain it back
Record specimen, timing, units and limits before claiming a mechanism worked.
Takeaway
Record specimen, timing, units and limits before claiming a mechanism worked.
Next: Compare the tools.
Sources and scope
General teaching, source-checked October 8, 2026. Expert and learner review remain pending. These lessons explain mechanisms and study interpretation; current choices are owned by the care plan and the local-priming question.